Prevalence and economic burden of cardiovascular diseases in France in 2013 according to the national health insurance scheme database
Philippe Tuppin, Sébastien Rivière, Alexandre Rigault, Stéphane Tala, Jérôme Drouin, Laurence Pestel, Pierre Denis, Christelle Gastaldi-Ménager, Claude Gissot, Yves Juillière, Anne Fagot-Campagna, Philippe Tuppin, Sébastien Rivière, Alexandre Rigault, Stéphane Tala, Jérôme Drouin, Laurence Pestel, Pierre Denis, Christelle Gastaldi-Ménager, Claude Gissot, Yves Juillière, Anne Fagot-Campagna
Abstract
Background: Cardiovascular diseases (CVDs) constitute the second leading cause of death in France. The Système national d'information interrégimes de l'assurance maladie (SNIIRAM; national health insurance information system) can be used to estimate the national medical and economic burden of CVDs.
Objectives: To describe the rates, characteristics and expenditure of people reimbursed for CVDs in 2013.
Methods: Among 57 million general health scheme beneficiaries (86% of the French population), people managed for CVDs were identified using algorithms based on hospital diagnoses either during the current year (acute phase) or over the previous 5 years (chronic phase) and long-term diseases. The reimbursed costs attributable to CVDs were estimated.
Results: A total of 3.5 million people (mean age, 71 years; 42% women) were reimbursed by the general health scheme for CVDs (standardized rate, 6.5%; coronary heart disease, 2.7%; arrhythmias/conduction disorders, 2.1%; stroke, 1.1%; heart failure, 1.1%). These frequencies increased with age and social deprivation, and were higher in Northern and Eastern France and Réunion Island. The total sum reimbursed by all schemes for CVDs was € 15.1 billion (50% for hospital care and 43% for outpatient care [including 15% for drugs and 12% for nurses/physiotherapists]); coronary heart disease accounted for € 4 billion, stroke for € 3.5 billion and heart failure for € 2.5 billion (i.e. 10% of the total expenditure reimbursed by all national health insurance schemes for all conditions).
Conclusion: CVDs constitute the leading group in terms of numbers of patients reimbursed and total reimbursed expenditure, despite a probable underestimation of both numbers and expenditure.
Keywords: Cardiovascular diseases; Comorbidities; Comorbidités; Costs; Coûts; Maladies cardiovasculaires; Prevalence; Prévalence; SNIIRAM; Sniiram.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.
Source: PubMed